Hepatic targeting of the centrally active cannabinoid 1 receptor (CB(1)R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes

Over-activation of the endocannabinoid/CB(1)R system is a hallmark feature of obesity and its related comorbidities, most notably type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD). Although the use of drugs that widely block the CB(1)R was found to be highly effective in treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Shira, Hinden, Liad, Naim, Meital Ben-David, Baraghithy, Saja, Permyakova, Anna, Azar, Shahar, Nasser, Taher, Portnoy, Emma, Agbaria, Majd, Nemirovski, Alina, Golomb, Gershon, Tam, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Publishers 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900386/
https://www.ncbi.nlm.nih.gov/pubmed/36442615
http://dx.doi.org/10.1016/j.jconrel.2022.11.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900386/
https://www.ncbi.nlm.nih.gov/pubmed/36442615
http://dx.doi.org/10.1016/j.jconrel.2022.11.040

Ejemplares similares